ArticleBiochemical and biophysical research communications2007
Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine.
Article in Biochemical and biophysical research communications, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 95 citations in OpenAlex.
- Article
- Deciphering Urogenital Cancers through Proteomic Biomarkers: A Systematic Review and Meta-Analysis.Cancers · 2023Review
- Urinary endogenous peptides as biomarkers for prostate cancer.Oncology letters · 2023Article
- Nuclear magnetic resonance-based metabolomics and metabolic pathway networks from patient-matched esophageal carcinoma, adjacent noncancerous tissues and urine.World journal of gastroenterology · 2019Article
- Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics.Journal of food and drug analysis · 2019Review
- Exploring potential biomarkers of early stage esophageal squamous cell carcinoma in pre- and post-operative serum metabolomic fingerprint spectrum usingAmerican journal of translational research · 2019Article
- Review
- Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.Frontiers in oncology · 2018Review
- MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers.Clinical proteomics · 2018Article
- NMR-based metabolomic techniques identify potential urinary biomarkers for early colorectal cancer detection.Oncotarget · 2017Article
- Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease.PloS one · 2017Article
- Gastrointestinal endoscopy biopsy derived proteomic patterns predict indeterminate colitis into ulcerative colitis and Crohn's colitis.World journal of gastrointestinal endoscopy · 2015Article
- Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer.Proteome science · 2015Article
- Advances in urinary protein biomarkers for urogenital and non-urogenital pathologies.Biochemia medica · 2015Review
- Diagnosis of inflammatory bowel disease: Potential role of molecular biometrics.World journal of gastrointestinal surgery · 2014Review
- Urine proteomes of healthy aging humans reveal extracellular matrix (ECM) alterations and immune system dysfunction.Age (Dordrecht, Netherlands) · 2014Article
- Article
- Transient and persistent metabolomic changes in plasma following chronic cigarette smoke exposure in a mouse model.PloS one · 2014Article
- The present and future of prostate cancer urine biomarkers.International journal of molecular sciences · 2013Review
- Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.Nature reviews. Urology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
The heterogeneous progression to the development of prostate cancer (PCa) has precluded effective early detection screens. Existing prostate cancer screening paradigms have relatively poor specificity for cancer relative to other prostate diseases, commonly benign prostatic hyperplasia (BPH). A method for discrimination of BPH, HGPIN, and PCa urine proteome was developed through testing 407 patient samples using matrix assisted laser desorption-mass spectrometry time of flight (MALDI-TOF). Urine samples were adsorbed to reverse phase resin, washed, and the eluant spotted directly for MALDI-TOF analysis of peptides. The processing resolved over 130 verifiable signals of a mass range of 1000-5000 m/z to suggest 71.2% specificity and 67.4% sensitivity in discriminating PCa vs. BPH. Comparing BPH and HGPIN resulted in 73.6% specificity and 69.2% sensitivity. Comparing PCa and HGPIN resulted in 80.8% specificity and 81.0% sensitivity. The high throughput, low-cost assay method developed is amenable for large patient numbers required for supporting biomarker identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.